XTX202 in Patients With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT05052268. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX202 in Patients With Advanced Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX202 in Patients with Advanced Solid Tumors
Study identification
- NCT ID
- NCT05052268
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 95 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 17, 2022
- Primary completion
- Mar 21, 2025
- Completion
- Mar 24, 2025
- Last update posted
- May 27, 2026
2022 – 2025
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UC San Diego Moores Cancer Center | La Jolla | California | 92093 | — |
| Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| University of California Los Angeles | Los Angeles | California | 90095 | — |
| Hoag Memorial Hospital Presbyterian- Newport Beach | Newport Beach | California | 92663 | — |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20007 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| University of Iowa Hospitals and Clinics | Iowa City | Iowa | 52242 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| HealthPartners Cancer Center at Regions Hospital | Saint Paul | Minnesota | 55101 | — |
| Atlantic Health System/Morristown Medical Center | Morristown | New Jersey | 07960 | — |
| Rutgers Cancer Institute of NJ | New Brunswick | New Jersey | 08903 | — |
| Carolina BioOncology Institute | Huntersville | North Carolina | 28078 | — |
| The Ohio State University Wexner Medical Center James Cancer Hospital and Solove Research Institute | Columbus | Ohio | 43210 | — |
| UPMC Hillman Cancer Center Pavilion | Pittsburgh | Pennsylvania | 15213 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05052268, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 27, 2026 · Synced Sep 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05052268 live on ClinicalTrials.gov.